EUVIMEDEUVIMED entdecken
Multizentrische Studie

PD‐L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non–small cell lung cancer with uncommon EGFR mutations treated with first‐line second‐generation EGFR‐tyrosine kinase inhibitors

Hongping Jin iD, Yue Wang, Yidan Zhang, Yiqing Wu, Tengfei Liu, Jianlin Xu, Tianqing Chu iD, Hua Zhong, Huizhen Yang, Runbo Zhong iD

Cancer · 2026

DOI: 10.1002/cncr.70460 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2026. Verfasst von Hongping Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Second‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are key first‐line therapies for advanced non–small cell lung cancer (NSCLC) with uncommon EGFR mutations, with risk stratification mainly based on EGFR mutation subtypes. Emerging evidence suggests programmed death‐ligand 1 (PD‐L1) expression may affect EGFR‐TKI efficacy. This study compared associations of PD‐L1 expression and EGFR mutation subtypes with outcomes in patients receiving first‐line second‐generation EGFR‐TKI monotherapy.

Methods

This dual‐center retrospective real‐world study included 215 patients with advanced NSCLC harboring uncommon EGFR mutations. Efficacy was evaluated across mutation subtypes (L861Q, G719X, S768I, other single‐site, compound mutations). Stratified analyses by PD‐L1 expression were performed, with prognostic value explored in primary lung lesions and metastatic lymph nodes. Primary end points include progression‐free survival (PFS), objective response rate (ORR), and disease control rate (DCR).

Results

The median PFS for all patients was 14.07 months (ORR, 49.3%; DCR, 89.8%). No statistically significant differences in ORR, DCR, or median PFS were observed among uncommon EGFR mutation subtypes. In contrast, high PD‐L1 expression was significantly associated with shorter PFS. Furthermore, PD‐L1 expression (tumor proportion score [TPS] ≥1%) in primary lung lesions was associated with shorter PFS, whereas no similar association was observed in metastatic lymph nodes.

Conclusion

In advanced NSCLC with uncommon EGFR mutations, first‐line second‐generation EGFR‐TKI monotherapy shows no statistically significant efficacy differences across mutation subtypes. PD‐L1 expression is inversely associated with outcomes, with prognostic value differing between primary tumors and metastatic lymph nodes, highlighting the importance of tissue sampling site in risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenCarcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedErbB ReceptorsMutationPrognosisRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

NSCLCPD‐L1heterogeneitysecond‐generation EGFR‐TKIuncommon EGFR mutations

Substanzen

B7-H1 AntigenCD274 protein, humanEGFR protein, humanErbB ReceptorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Respiratory and Critical Care Medicine, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.

ORCID-Profile: Hongping Jin, Tianqing Chu, Runbo Zhong

Förderung

  • Natural Science Foundation of Shanghai

Zitieren

APA

Jin, H., Wang, Y., Zhang, Y., Wu, Y., Liu, T., Xu, J., Chu, T., Zhong, H., Yang, H., & Zhong, R. (2026). PD‐L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non–small cell lung cancer with uncommon EGFR mutations treated with first‐line second‐generation EGFR‐tyrosine kinase inhibitors. Cancer. https://doi.org/10.1002/cncr.70460

Vancouver

Jin H, Wang Y, Zhang Y, Wu Y, Liu T, Xu J, et al. PD‐L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non–small cell lung cancer with uncommon EGFR mutations treated with first‐line second‐generation EGFR‐tyrosine kinase inhibitors. Cancer. 2026. doi:10.1002/cncr.70460

BibTeX
@article{Jin2026,
  author = {Jin, Hongping and Wang, Yue and Zhang, Yidan and Wu, Yiqing and Liu, Tengfei and Xu, Jianlin and Chu, Tianqing and Zhong, Hua and Yang, Huizhen and Zhong, Runbo},
  title = {PD‐L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non–small cell lung cancer with uncommon EGFR mutations treated with first‐line second‐generation EGFR‐tyrosine kinase inhibitors},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70460}
}
Kostenlos starten →